Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LUCD
stocks logo

LUCD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.43M
+19.06%
-0.102
-48.4%
1.65M
+99.58%
-0.095
-81.73%
2.04M
+75.62%
-0.083
+3.13%
Estimates Revision
The market is revising Downward the revenue expectations for Lucid Diagnostics Inc. (LUCD) for FY2025, with the revenue forecasts being adjusted by -4.75% over the past three months. During the same period, the stock price has changed by -22.63%.
Revenue Estimates for FY2025
Revise Downward
down Image
-4.75%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-5.19%
In Past 3 Month
Stock Price
Go Down
down Image
-22.63%
In Past 3 Month
Wall Street analysts forecast LUCD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUCD is 3.75 USD with a low forecast of 2.50 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast LUCD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUCD is 3.75 USD with a low forecast of 2.50 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.060
sliders
Low
2.50
Averages
3.75
High
8.00
Current: 1.060
sliders
Low
2.50
Averages
3.75
High
8.00
BTIG
Mark Massaro
Buy
maintain
$2
2025-09-05
Reason
BTIG
Mark Massaro
Price Target
$2
2025-09-05
maintain
Buy
Reason
BTIG analyst Mark Massaro raised the firm's price target on Lucid Diagnostics to $2.50 from $2 and keeps a Buy rating on the shares. Attending the CMS meeting to discuss the merits of Medicare coverage for Lucid's EsoGuard test, the firm heard "unanimously positive statements" from all clinicians supporting the "obvious use case" for EsoGuard, the analyst tells investors in a research note.
Ascendiant
Buy
maintain
2025-06-06
Reason
Ascendiant
Price Target
2025-06-06
maintain
Buy
Reason
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$7 → $7.5
2025-04-21
Reason
Ascendiant Capital
Edward Woo
Price Target
$7 → $7.5
2025-04-21
Maintains
Strong Buy
Reason
Needham
Mike Matson
Strong Buy
Reiterates
$3
2025-04-11
Reason
Needham
Mike Matson
Price Target
$3
2025-04-11
Reiterates
Strong Buy
Reason
Cantor Fitzgerald
Ross Osborn
Buy
Reiterates
$2
2025-03-26
Reason
Cantor Fitzgerald
Ross Osborn
Price Target
$2
2025-03-26
Reiterates
Buy
Reason
Needham
Mike Matson
Strong Buy
Maintains
$2.5 → $3
2025-03-24
Reason
Needham
Mike Matson
Price Target
$2.5 → $3
2025-03-24
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Lucid Diagnostics Inc (LUCD.O) is -2.93, compared to its 5-year average forward P/E of -2.08. For a more detailed relative valuation and DCF analysis to assess Lucid Diagnostics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.08
Current PE
-2.93
Overvalued PE
-0.10
Undervalued PE
-4.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.63
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.04
Undervalued EV/EBITDA
-5.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
26.59
Current PS
0.00
Overvalued PS
72.19
Undervalued PS
-19.02
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

LUCD News & Events

Events Timeline

(ET)
2025-11-12
08:02:57
Lucid Diagnostics Announces Q3 Earnings Per Share of 10 Cents, Exceeding Consensus Estimate of 9 Cents
select
2025-09-10 (ET)
2025-09-10
08:32:09
Lucid Diagnostics Prices 25M Share Spot Secondary at $1.00
select
2025-09-09 (ET)
2025-09-09
16:05:32
Lucid Diagnostics Reveals Common Stock Offering, Amount Not Disclosed
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
11-26NASDAQ.COM
Wednesday's Underperforming Sectors: Diagnostics, Medical Instruments, and Supplies

  • Market Performance: Medical instruments and supplies shares are lagging the market, down approximately 0.3% on Wednesday.

  • Key Contributors: Pacific Biosciences of California saw a significant drop of about 13.5%, while Butterfly Network declined by around 9.1%.

  • Sector Overview: The diagnostics, medical instruments, and supplies sector is highlighted as a laggard in the market performance for the day.

  • Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.

[object Object]
Preview
2.0
11-20Newsfilter
Lucid Diagnostics Recognized as a Top-Ranking Honoree in GenomeWeb's 2025 Best Places to Work

  • Recognition of Lucid Diagnostics: Lucid Diagnostics Inc. has been awarded the title of the best workplace in its size category by GenomeWeb's 2025 Best Places to Work program, highlighting its positive workplace culture and commitment to employee development.

  • Company Focus: Lucid Diagnostics specializes in cancer prevention through its innovative EsoGuard® Esophageal DNA Test, aimed at early detection of esophageal precancer in patients with gastroesophageal reflux disease (GERD).

  • Leadership Statement: Shaun O'Neil, President and COO of Lucid, expressed pride in the recognition, emphasizing the company's dedication to a culture of service and excellence for both patients and employees.

  • About GenomeWeb: GenomeWeb is a leading news organization that covers the molecular biology research and diagnostics sectors, providing insights and analysis to professionals in the life sciences field.

[object Object]
Preview
1.0
11-13Newsfilter
Lucid Diagnostics to Join Canaccord Genuity's MedTech, Diagnostics, and Digital Health & Services Forum

  • Company Participation: Lucid Diagnostics Inc. will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025, in New York City, with CFO Dennis McGrath available for one-on-one investor meetings.

  • Focus on Cancer Prevention: Lucid Diagnostics specializes in cancer prevention, particularly for patients with gastroesophageal reflux disease (GERD), offering the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device for early detection of esophageal precancer.

  • Forward-Looking Statements: The press release includes forward-looking statements that involve risks and uncertainties, such as stock price volatility, regulatory challenges, and market acceptance of Lucid's products.

  • Monitoring COVID-19 Impact: Lucid continues to assess the impact of the COVID-19 pandemic on its business operations, acknowledging that new risks may arise that are difficult to predict.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Lucid Diagnostics Inc (LUCD) stock price today?

The current price of LUCD is 1.06 USD — it has increased 1.92 % in the last trading day.

arrow icon

What is Lucid Diagnostics Inc (LUCD)'s business?

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.

arrow icon

What is the price predicton of LUCD Stock?

Wall Street analysts forecast LUCD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUCD is 3.75 USD with a low forecast of 2.50 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Lucid Diagnostics Inc (LUCD)'s revenue for the last quarter?

Lucid Diagnostics Inc revenue for the last quarter amounts to 1.21M USD, increased 3.33 % YoY.

arrow icon

What is Lucid Diagnostics Inc (LUCD)'s earnings per share (EPS) for the last quarter?

Lucid Diagnostics Inc. EPS for the last quarter amounts to -0.10 USD, decreased -60.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Lucid Diagnostics Inc (LUCD)'s fundamentals?

The market is revising Downward the revenue expectations for Lucid Diagnostics Inc. (LUCD) for FY2025, with the revenue forecasts being adjusted by -4.75% over the past three months. During the same period, the stock price has changed by -22.63%.
arrow icon

How many employees does Lucid Diagnostics Inc (LUCD). have?

Lucid Diagnostics Inc (LUCD) has 72 emplpoyees as of December 05 2025.

arrow icon

What is Lucid Diagnostics Inc (LUCD) market cap?

Today LUCD has the market capitalization of 140.28M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free